Literature DB >> 15978829

Screening for lung cancer: New horizons?

Antonio Rossi1, Paolo Maione, Giuseppe Colantuoni, Filomena Del Gaizo, Ciro Guerriero, Dario Nicolella, Carmine Ferrara, Cesare Gridelli.   

Abstract

Lung cancer remains the leading cause of cancer-related deaths in the world. At present, the only high rate of cure therapy is surgical resection at early stage of disease. Early detection could potentially decrease lung cancer mortality suggesting that this cancer should be a good candidate for screening. Results of trials involving chest X-ray, sputum cytology and low-dose computed tomography (CT) are discussed here. The latter tool offers advantages over chest X-ray, but final results from controlled well conducted trials are necessary before the real utility of CT mass screening can be determined. Further approaches to secondary prevention such as screening with positron emission tomography (PET), autofluorescence bronchoscopy and biomarkers hold great promise for the future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15978829     DOI: 10.1016/j.critrevonc.2005.04.007

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  7 in total

1.  Secondary prevention at 360°: the important role of diagnostic imaging.

Authors:  Anna Micaela Ciarrapico; Guglielmo Manenti; Chiara Pistolese; Sebastiano Fabiano; Roberto Fiori; Andrea Romagnoli; Gianluigi Sergiacomi; Matteo Stefanini; Giovanni Simonetti
Journal:  Radiol Med       Date:  2015-01-09       Impact factor: 3.469

2.  Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers.

Authors:  Kristy L Richards; Baili Zhang; Menghong Sun; Wenli Dong; Jennifer Churchill; Linda L Bachinski; Charmaine D Wilson; Keith A Baggerly; Guosheng Yin; D Neil Hayes; Ignacio I Wistuba; Ralf Krahe
Journal:  Cancer       Date:  2010-10-13       Impact factor: 6.860

Review 3.  New screening method for lung cancer by detecting volatile organic compounds in breath.

Authors:  C Belda-Iniesta; J de Castro Carpeño; J A Carrasco; V Moreno; E Casado Sáenz; J Feliu; M Sereno; F García Río; J Barriuso; M González Barón
Journal:  Clin Transl Oncol       Date:  2007-06       Impact factor: 3.340

Review 4.  Lung cancer screening: the way forward.

Authors:  J K Field; S W Duffy
Journal:  Br J Cancer       Date:  2008-07-29       Impact factor: 7.640

5.  The assessment of the role of baseline low-dose CT scan in patients at high risk of lung cancer.

Authors:  Katarzyna Kołaczyk; Anna Walecka; Tomasz Grodzki; Jacek Alchimowicz; Andrzej Smereczyński; Radosław Kiedrowicz
Journal:  Pol J Radiol       Date:  2014-07-18

6.  Identification of a three-miRNA signature as a blood-borne diagnostic marker for early diagnosis of lung adenocarcinoma.

Authors:  Yang Wang; Hua Zhao; Xujie Gao; Feng Wei; Xinwei Zhang; Yanjun Su; Changli Wang; Hui Li; Xiubao Ren
Journal:  Oncotarget       Date:  2016-05-03

7.  Prediction of MiR-21-5p in Promoting the Development of Lung Adenocarcinoma via PDZD2 Regulation.

Authors:  Shengjin Cui; Shuang Lou; Weiquan Guo; Shihui Jian; Yunfeng Wu; Xintong Liu; Xi Lan; Xingwang Jia
Journal:  Med Sci Monit       Date:  2020-06-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.